Remedy to Diabetes Distress (R2D2): A Scalable Screen to Treat Program for School-age Families

Description

This R01 is in response to RFA-DK-19-021, Treating Diabetes Distress to Improve Glycemic Outcomes in Type 1 Diabetes. The objective is to test the feasibility and acceptability of a novel, practical, and potentially scalable screen to treat program for diabetes distress in families of school-age children with T1D (called Remedy to Diabetes Distress \[R2D2\]) and to test the initial efficacy of R2D2 to reduce diabetes distress to improve children's glycemic control.

Conditions

Type 1 Diabetes

Talk to us

Study Overview

On this page

Study Details

Study overview

This R01 is in response to RFA-DK-19-021, Treating Diabetes Distress to Improve Glycemic Outcomes in Type 1 Diabetes. The objective is to test the feasibility and acceptability of a novel, practical, and potentially scalable screen to treat program for diabetes distress in families of school-age children with T1D (called Remedy to Diabetes Distress \[R2D2\]) and to test the initial efficacy of R2D2 to reduce diabetes distress to improve children's glycemic control.

Remedy to Diabetes Distress (R2D2): A Scalable Screen to Treat Program for School-age Families

Remedy to Diabetes Distress (R2D2): A Scalable Screen to Treat Program for School-age Families

Condition
Type 1 Diabetes
Intervention / Treatment

-

Contacts and Locations

Jacksonville

Nemours Children's Health, Jacksonville, Florida, United States, 32207

Kansas City

Children's Mercy Kansas City, Kansas City, Missouri, United States, 64108

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * child age between 8-12 years, physician confirmed T1D diagnosis,
  • * either the child or the parent or both the child and parent report diabetes distress levels at or above clinical cut-points,
  • * child is on an intensive insulin regimen (pump or MDI).
  • * children on a conventional insulin regimen, children and/or parents who do not report diabetes distress levels at or above the clinical cut-points,
  • * children who have an allergy or sensitivity to the adhesive and/or skin preparation used for CGM, children with a comorbid chronic condition (e.g., renal disease),
  • * children and parents who do not speak English.

Ages Eligible for Study

8 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Nemours Children's Clinic,

Susana R Patton, PhD, PRINCIPAL_INVESTIGATOR, Nemours Children's Health

Study Record Dates

2026-08-31